Literature DB >> 20715975

Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.

L Silvia Munoz-Price1, Teresa Zembower, Sudhir Penugonda, Paul Schreckenberger, Mary Alice Lavin, Sharon Welbel, Dana Vais, Mirza Baig, Sunita Mohapatra, John P Quinn, Robert A Weinstein.   

Abstract

OBJECTIVE: To characterize the clinical outcomes of patients with bloodstream infection caused by carbapenem-resistant Acinetobacter baumannii during a 2-state monoclonal outbreak.
DESIGN: Multicenter observational study. Setting. Four tertiary care hospitals and 1 long-term acute care hospital.
METHODS: A retrospective medical chart review was conducted for all consecutive patients during the period January 1, 2005, through April 30, 2006, for whom 1 or more blood cultures yielded carbapenem-resistant A. baumannii.
RESULTS: We identified 86 patients from the 16-month study period. Their mortality rate was 41%; of the 35 patients who died, one-third (13) had positive blood culture results for carbapenem-resistant A. baumannii at the time of death. Risk factors associated with mortality were intensive care unit stay, malignancy, and presence of fever and/or hypotension at the time blood sample for culture was obtained. Only 5 patients received adequate empirical antibiotic treatment, but the choice of treatment did not affect mortality. Fifty-seven patients (66.2%) had a single positive blood culture result for carbapenem-resistant A. baumannii; the only factor associated with a single positive blood culture result was the presence of decubitus ulcers. Interestingly, during the study period, a transition from single to multiple positive blood culture results was observed. Four patients, 3 of whom were in a burn intensive care unit, were bacteremic for more than 30 days (range, 36-86 days).
CONCLUSIONS: To our knowledge, this is the first time a study has described 2 patterns of bloodstream infection with A. baumannii: single versus multiple positive blood culture results, as well as a subset of patients with prolonged bacteremia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20715975     DOI: 10.1086/656247

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  34 in total

Review 1.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

2.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

3.  Genome sequences of four divergent multidrug-resistant Acinetobacter baumannii strains isolated from patients with sepsis or osteomyelitis.

Authors:  Daniel V Zurawski; Mitchell G Thompson; Christin N McQueary; Malcolm N Matalka; Jason W Sahl; David W Craft; David A Rasko
Journal:  J Bacteriol       Date:  2012-03       Impact factor: 3.490

4.  Diabetic murine models for Acinetobacter baumannii infection.

Authors:  Guanpingsheng Luo; Brad Spellberg; Teclegiorgis Gebremariam; Michael Bolaris; Hongkyu Lee; Yue Fu; Samuel W French; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2012-03-02       Impact factor: 5.790

5.  Whole-Genome Sequencing Elucidates Epidemiology of Nosocomial Clusters of Acinetobacter baumannii.

Authors:  Stefanie Willems; Stefanie Kampmeier; Stefan Bletz; Annelene Kossow; Robin Köck; Frank Kipp; Alexander Mellmann
Journal:  J Clin Microbiol       Date:  2016-06-29       Impact factor: 5.948

6.  Next-Generation Epidemiology: Using Real-Time Core Genome Multilocus Sequence Typing To Support Infection Control Policy.

Authors:  John P Dekker; Karen M Frank
Journal:  J Clin Microbiol       Date:  2016-09-14       Impact factor: 5.948

7.  Utility of Whole-Genome Sequencing in Characterizing Acinetobacter Epidemiology and Analyzing Hospital Outbreaks.

Authors:  Margaret A Fitzpatrick; Egon A Ozer; Alan R Hauser
Journal:  J Clin Microbiol       Date:  2015-12-23       Impact factor: 5.948

8.  Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.

Authors:  John S Esterly; Milena Griffith; Chao Qi; Michael Malczynski; Michael J Postelnick; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 9.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

10.  "Airborne assault": a new dimension in Acinetobacter baumannii transmission*.

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2013-08       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.